

5 October 2023

Dear Shareholder

2023 ANNUAL GENERAL MEETING

Cleo Diagnostics Ltd (ASX: COV) ("the Company") advises that the 2023 Annual General Meeting of the shareholders of the Company is scheduled to be held at Hudson Institute of Medical Research, Translational Research Facility, Seminar Room 2, 27-31 Wright Street, Clayton VIC 3168 on Wednesday, 22 November 2023 at 4:00pm (Melbourne time) ("the Meeting").

In accordance with section 110D(1) of the Corporations Act 2001 (Cth) (Corporations Act), the Company will not be sending hard copies of the NOM to shareholders unless a shareholder has requested a hardcopy of the NOM or made an election for the purposes of 110E of the Corporations Act to receive documents from the Company in physical form. The NOM is made available to shareholders electronically. The Notice of the Meeting can be viewed, accessed and downloaded at https://cleodx.com/investors/asx-announcements/ or via the following direct link to the ASX announcements platform of the Company: https://www.asx.com.au/markets/company/cov

Those shareholders who receive their company communications in the post will therefore receive a printed copy of this announcement and their personalised proxy form.

Alternatively, shareholders who receive their communications electronically will receive an email from the Company's share registry, Xcend Pty Ltd, with links directing them to this notice and the online voting portal https://investor.xcend.app

Shareholders are strongly encouraged to vote by lodging a directed proxy appointing the Chairman before 4.00pm (Melbourne time) on Monday 20 November 2023. A personalised proxy form is enclosed. Proxies can be lodged in accordance with instructions in the enclosed personalised proxy form.

The Company thanks shareholders for their ongoing support.

Ms Pauline Moffatt
Company Secretary



Level 2, 480 Collins Street, Melbourne, VIC, 3000 ACN 655 717 169 **T** +61 3 9614 0600 **E** office@cleodx.com